Preparation of a photo-released ruthenium complex and its application in combating drug-resistant tumors
The photorelease ruthenium complex prepared through Suzuki coupling reaction uses photo activation to generate internal peroxygen compounds, solving the problem of limited application of targeted drug resistance and photodynamic therapy in hypoxia environments, and realizing drug-resistant lung cancer The efficient killing of cells provides a solution to anti-drug-resistant tumors in novel photochemotherapy.
Patent Information
- Application Number
- CN202211729734.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-12-30
AI Technical Summary
Among the existing treatment methods for lung cancer, targeted drugs are prone to resistance during use, and photodynamic therapy is limited in the application of hypoxic environment, making it difficult to effectively kill aggressive and drug-resistant cancer cells.
A new photoreleasing ruthenium complex was prepared by Suzuki coupling reaction, which produced internal peroxy compounds through photoactivation, and was used for photochemotherapy to resist drug-resistant tumors. The preparation method of the complex includes heating and reflux reaction under the protection of an inert gas to generate a bpy-en ligand and a Ru(dmp)2Cl2 precursor, followed by reaction with a tpy-en ligand and ammonium hexafluorophosphate to form [Ru( 2,9-dmp)2(bpy-en)](PF6)2 light releases ruthenium complex.
The light-releasing ruthenium complex has strong growth and proliferation inhibition ability on human non-small cell lung cancer 5-fluorouracil resistant cells under light conditions. The IC50 value is 0.66mM, providing a new idea for the development of photochemotherapy and anti-drug-resistant tumors. Drugs or anti-tumor metal photosensitizers.
Smart Images

Figure CN116284145B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemistry, relates to the field of photochemotherapy medicine, and specifically relates to the preparation of a light-released ruthenium complex and its application in combating drug-resistant tumors. Background Art
[0002] Lung cancer is one of the most common malignant tumors in the world. According to statistics, the number of people who die from lung cancer each year in the United States is more than the number of people who die from colon cancer, breast cancer and prostate cancer combined, and the 5-year lung cancer survival rate is only 18.4. Non-small cell lung cancer accounts for about 80% of all lung cancers, and about 75% of non-small cell lung cancer patients are already in the middle and late stages when they are discovered. Therefore, the development of non-small cell lung cancer drugs has always been a hot topic of research.
[0003] Drug therapy is one of the most important treatments for cancer patients. With the use of drugs, tumor cells acquire the ability to resist the effects of drugs. However, almost all drugs cannot avoid the development of drug resistance during treatment. In recent years, the application of targeted drugs has achieved good therapeutic effects. Among them, molecular targeted drugs mainly target abnormal tumor signaling pathways, have the characteristics of high selectivity, low toxicity, and high therapeutic index, and have become the main direction of the development of new anti-tumor drugs. However, the problem of drug resistance has largely limited its potential for clinical application.
[0004] Photodynamic therapy (PDT) is a non-invasive / minimally invasive cancer treatment method. It has attracted much attention in the field of tumor treatment due to its advantages such as high selectivity, low toxicity and side effects, and low drug resistance. The principle of photodynamic therapy is to use photosensitizers (PSs) under laser irradiation to produce reactive oxygen species (ROS), which then inhibits the growth and proliferation of tumor cells and causes their death. However, many invasive and drug-resistant cancers are characterized by hypoxia, and tumor hypoxia seriously limits the application of PDT. At present, an alternative photodynamic therapy method, namely photochemotherapy, has emerged, which can produce active intermediates and products through self-limiting oxygen-independent photochemical reactions, and finally induce tumor cell death under hypoxia. Its classic mechanism is to undergo a photosubstitution reaction through the triplet state excited by the metal center. Therefore, providing a new type of light-releasing ruthenium complex has important application prospects. Summary of the invention
[0005] In order to overcome the above-mentioned deficiencies of the prior art, the primary purpose of the present invention is to provide a novel light-releasing ruthenium complex.
[0006] The second object of the present invention is to provide a method for preparing the above-mentioned light-releasing ruthenium complex. The present invention adopts Suzuki coupling reaction to prepare the light-releasing ruthenium complex.
[0007] The third object of the present invention is to provide the application of the above-mentioned light-released ruthenium complex. The complex has a strong photochemotherapeutic effect on drug-resistant cell lines of human non-small cell lung cancer and can be used to prepare photochemotherapeutic drugs or metal photosensitizers for drug-resistant tumors.
[0008] The above first object of the present invention is achieved by the following technical solutions:
[0009] A light-releasing ruthenium complex, the structure of which is shown below:
[0010]
[0011] The above second object of the present invention is achieved through the following technical solutions:
[0012] The method for preparing the light-released ruthenium complex described in the first invention object comprises the following steps:
[0013] S1. Under the protection of inert gas, 9-anthraceneboric acid, 5-bromo-2,2′-bipyridyltetrakis(triphenylphosphine)palladium and anhydrous potassium carbonate are dissolved in an organic solvent, and the bpy-en ligand is obtained by heating under reflux reaction, extraction and purification;
[0014] S2, under the protection of inert gas, ruthenium chloride (III) hydrate, lithium chloride and 2,9-dimethyl-1,10-phenanthroline are dissolved in an organic solvent, and a Ru(dmp)2Cl2 precursor is prepared by reflux reaction, enrichment precipitation and precipitate washing;
[0015] S3. Dissolve the precursor Ru(dmp)2Cl2 and tpy-en ligand in an organic solvent, add a saturated aqueous solution of ammonium hexafluorophosphate after heating reaction, and obtain a light-releasing ruthenium complex after stirring reaction.
[0016] Preferably, in step S1, the molar ratio of 9-anthraceneboric acid, 5-bromo-2,2′-bipyridine and anhydrous potassium carbonate is 1:1:3, and the amount of tetrakis(triphenylphosphine)palladium is 3 mol%.
[0017] Preferably, in step S1, the heating reflux reaction is a heating reflux reaction at 100-115° C. for 8-15 h. More preferably, the heating reflux reaction is a heating reflux reaction at 115° C. for 12 h.
[0018] Preferably, in step S2, the reflux reaction time is 8 to 15 hours. More preferably, the reflux reaction time is 12 hours.
[0019] Preferably, in step S2, the molar ratio of ruthenium (III) chloride hydrate, lithium chloride and 2,9-dimethyl-1,10-phenanthroline (2,9-dmp) is 3:8.9:6.
[0020] Preferably, in step S3, the molar ratio of the tpy-en ligand to the RuCl2(2,9-dmp)2 precursor is 1:1.
[0021] Preferably, in step S3, the heating reaction is carried out at 80-85° C. for 8-15 hours. More preferably, the heating reaction is carried out at 80° C. for 12 hours.
[0022] The third object of the present invention is achieved by the following technical solutions:
[0023] The first invention object is to use the light-released ruthenium complex in the preparation of anti-drug-resistant tumor drugs.
[0024] Preferably, the anti-drug resistant tumor drug is a drug against drug resistance of non-small cell lung cancer. More preferably, the anti-drug resistant tumor drug is a drug against drug resistance of 5-fluorouracil of non-small cell lung cancer.
[0025] The research found that the ruthenium complex provided by the present invention has a strong photochemotherapeutic effect on human non-small cell lung cancer 5-fluorouracil-resistant cells (A549 / 5-FU cells), and has a strong growth and proliferation inhibition ability (IC 50 0.66mM), its IC 50 The value of PI is 67.17, and that of PI is as high as 102, which is expected to be used in the preparation of photochemotherapeutic drugs for anti-resistant tumors or antitumor metal photosensitizers.
[0026] The present invention also provides a photochemotherapeutic anti-resistant tumor drug or anti-tumor metal photosensitizer, wherein the drug or photosensitizer uses the light-releasing ruthenium complex described in the first invention purpose as a main active ingredient.
[0027] Preferably, the drug or photosensitizer further comprises a pharmaceutically acceptable carrier and / or excipient. That is, the drug or photosensitizer uses a binuclear metal ruthenium complex as a main active ingredient, mixed with a pharmaceutically acceptable carrier and / or excipient to prepare a composition, and prepared into a clinically acceptable dosage form.
[0028] Furthermore, the excipient refers to diluents, adhesives, lubricants, disintegrants, solubilizers, stabilizers and other pharmaceutical matrices that can be used in the pharmaceutical field.
[0029] Furthermore, the carrier is an acceptable functional pharmaceutical excipient in the pharmaceutical field, including surfactants, suspending agents, emulsifiers and some new pharmaceutical polymer materials, such as cyclodextrin, chitosan, polylactic acid (PLA), polyglycolic acid-polylactic acid copolymer (PLGA), hyaluronic acid, etc.
[0030] Furthermore, the present invention has no particular limitation on the dosage form of the above-mentioned drugs or photosensitizers, and they can be prepared into tablets, capsules, suppositories, powder injections, etc., which are well known to those skilled in the art. The prepared preparations can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically). If some drugs are unstable under gastric conditions, they can be prepared into enteric-coated tablets.
[0031] Compared with the prior art, the present invention has the following beneficial effects:
[0032] The invention discloses a novel light-released ruthenium complex, which has a novel structure and the ability to produce new substances after light activation. It can release ligands and form endoperoxides to expose metal centers under light conditions (ligands 2,9-DMP, bpy-en and endoperoxidized bpy-en can be produced after light exposure), and has a strong photochemotherapeutic effect on human non-small cell lung cancer resistant cells. It has a strong growth and proliferation inhibition ability on human non-small cell lung cancer resistant cells under light conditions, which is of great significance for studying new light-released ruthenium complexes to resist resistant tumors, and provides a new idea for the clinical development of photochemotherapeutic drugs or anti-tumor metal photosensitizers. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 is the H NMR spectrum of bpy-en ligand;
[0034] Figure 2 This is the H NMR spectrum of the photo-released ruthenium complex [Ru(2,9-dmp)2(bpy-en)](PF6)2;
[0035] Figure 3 The ESI-MS image of the photo-released ruthenium complex [Ru(2,9-dmp)2(bpy-en)](PF6)2;
[0036] Figure 4 is the UV absorbance of the photo-released ruthenium complex [Ru(2,9-dmp)2(bpy-en)](PF6)2 in different solvents;
[0037] Figure 5 The changes in the ultraviolet absorption spectrum of the photo-released ruthenium complex [Ru(2,9-dmp)2(bpy-en)](PF6)2 after irradiation;
[0038] Figure 6 The results of mass spectrometry analysis of the photo-released ruthenium complex [Ru(2,9-dmp)2(bpy-en)](PF6)2 after irradiation;
[0039] Figure 7The photochemotherapeutic effect of the photoreleased ruthenium complex [Ru(2,9-dmp)2(bpy-en)](PF6)2 on 5-fluorouracil-resistant human non-small cell lung cancer cells. DETAILED DESCRIPTION
[0040] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in each embodiment of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0041] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0042] Example 1 Light-released ruthenium complex and preparation method thereof
[0043] The structural formula of the light-releasing ruthenium complex is shown below:
[0044]
[0045] The synthesis method of the light-released ruthenium complex specifically comprises the following steps:
[0046] (1) 5-(9-anthracenyl)-2,2'-bipyridine (bpy-en) ligand is generated by reacting 9-anthracene boronic acid with 5-bromo-2,2'-bipyridine:
[0047] Under N2 protection, 9-anthraceneboric acid (1.11 g, 5 mmol), 5-bromo-2,2′-bipyridine (1.17 g, 5 mmol), tetrakis(triphenylphosphine)palladium (3 mol%) and anhydrous potassium carbonate (2.07 g, 15 mmol) were placed in toluene / water (15 mL / 3 mL) and heated to reflux at 115°C for 12 h. After the reaction, the mixture was returned to room temperature and extracted three times with ethyl acetate. The combined extracts were dried over anhydrous sodium sulfate to obtain a crude product. Purification was performed using an alumina column (eluent: petroleum ether / ethyl acetate = 30 / 1) and further dried to obtain a white powder to obtain 5-(9-anthryl)-2,2′-bipyridine (bpy-en) ligand with a yield of 0.98 g (49.5%).
[0048] The H NMR spectrum of the product ( Figure 1 )for: 1H NMR (400MHz, DMSO-d6) δ8.78(d,J=6.2Hz,2H),8.73(d,J=1.9Hz,1H),8.68(d,J=8.1Hz,1H),8.55(d,J=7. 9Hz, 1H), 8.21 (d, J = 8.4Hz, 2H), 8.04 (ddd, J = 14.0, 7.9, 2.1Hz, 2H), 7.66–7.51 (m, 5H), 7.51–7.44 (m, 2H).
[0049] The chemical reaction equation above is as follows:
[0050]
[0051] (2) Ruthenium (III) chloride hydrate reacts with 2,9-dimethyl-1,10-phenanthroline (2,9-dmp) to form RuCl2(2,9-dmp)2 precursor:
[0052] Under N2 protection, ruthenium chloride (III) hydrate (0.62 g, 3 mmol), lithium chloride (0.38 g, 8.9 mmol) and 2,9-dimethyl-1,10-phenanthroline (2,9-dmp) (1.25 g, 6 mmol) were added to a round-bottom flask, and 20 mL of N,N-dimethylformamide was added, and then heated to reflux for 8 hours. After the reactants were cooled to room temperature, 30 mL of acetone was added, and the mixture was placed in a refrigerator and allowed to stand overnight. A purple-black precipitate was obtained by suction filtration, and the precipitate was washed alternately with cold water and acetone to obtain Ru(dmp)2Cl2 precursor with a yield of 24.3%.
[0053] The chemical reaction equation above is as follows:
[0054]
[0055] (3) The RuCl2(2,9-dmp)2 precursor reacts with the bpy-en ligand and then undergoes ion replacement with ammonium hexafluorophosphate to obtain a photo-released ruthenium complex:
[0056] The precursor Ru(dmp)2Cl2 (0.29 g, 0.5 mmol) and 5-(9-anthryl)-2,2′-bipyridine (tpy-en) (0.17 g, 0.5 mmol) were dissolved in ethylene glycol (25 mL) and heated at 80°C overnight. The mixture was then cooled to room temperature, and a saturated aqueous solution of ammonium hexafluorophosphate was added and stirred for 1 hour to obtain the target photo-released ruthenium complex ([Ru(2,9-dmp)2(bpy-en)](PF6)2). The crude product was purified by neutral alumina column chromatography (solvent: dichloromethane / acetonitrile = 3 / 1, V:V) to obtain the photo-released ruthenium complex [Ru(2,9-dmp)2(bpy-en)](PF6)2 as a red solid with a yield of 22.3%.
[0057] The H NMR spectrum of the product ( Figure 2 )for: 1 H NMR (400MHz, DMSO-d6) δ8.87(dd,J=8.3,3.7Hz,2H),8.81(d,J=8.3Hz,1H),8.71(s,1H),8.70(d,J=4.0Hz,1H),8.58(d,J=8 .3Hz,1H),8.40(d,J=8.8Hz,1H),8.35(d,J=8.3Hz,1H),8.27(d,J=9.1Hz,1H),8.15(d,J=7.8Hz,2H),8.10–7.99(m,3H),7. 92(d,J=8.3Hz,1H),7.78(t,J=8.0Hz,2H),7.69(d,J=8.4Hz,1H),7.62(t,J=8.0Hz,1H),7.58(d,J=8.3Hz,1H),7.54(t,J=8 .0Hz,1H),7.49–7.41(m,2H),7.23–7.10(m,4H),5.80(d,J=8.6Hz,1H),2.25(s,3H),2.01(s,3H),1.82(s,3H),1.73(s,3H).
[0058] ESI-MS of the product ( Figure 3 ) is: [M-2PF6] 2+ Found[C 52 H 40 N6Ru] 2+ :425.1180.
[0059] The chemical reaction equation above is as follows:
[0060]
[0061] Experimental Example 1 Characteristics and Performance Test of Photo-Releasable Ruthenium Complex
[0062] (1) Ultraviolet absorption properties of photo-released ruthenium complexes in different solvents
[0063] The quartz cuvettes containing different solvent solutions (ACN, DCM, DMF, DMSO, EA, EG, EtOH, H2O, MeOH, PBS) of the photo-released ruthenium complex (10 mM) were placed in a UV spectrophotometer to detect the absorbance of the solution. The results are shown in Figure 2. Figure 4 As shown. This indicates that the photo-released ruthenium complexes have similar ultraviolet absorption properties in different solvents.
[0064] (2) Changes in the UV-visible absorption spectrum of photo-released ruthenium complexes after illumination
[0065] A quartz cuvette containing a PBS solution of a photo-released ruthenium complex (10 mM) was placed under a white light source (total light dose of 11.6 J / cm 2 ), and the changes in the UV absorption spectrum of the solution were detected every 60 seconds. Figure 5 As shown, the ultraviolet absorption spectrum of the photo-released ruthenium complex undergoes a red shift and an isosbestic point appears after irradiation at 465nm, indicating that the ruthenium complex has the ability to produce new substances after photoactivation.
[0066] (3) Mass spectra of photo-released ruthenium complexes after illumination
[0067] The photo-releasing ruthenium complex was dissolved in chromatographic grade methanol and then irradiated under a white light source (light dose of 11.6 J / cm 2 ), and the solution after illumination was subjected to mass spectrometry analysis. Figure 6 As shown, it was found that after light irradiation, ligand 2,9-dmp, bpy-en and endoperoxidized bpy-en were produced, indicating that the ruthenium complex has the ability to release ligands to expose the metal center and produce endoperoxide compounds after photoactivation.
[0068] (4) Photochemotherapeutic activity of photoreleased ruthenium complexes on 5-fluorouracil-resistant human non-small cell lung cancer cells
[0069] The MTT colorimetric method was used to analyze the antiproliferative effect of the photo-released ruthenium complex on different tumor cells. MTT, whose Chinese name is thiazole blue, is a tetrazolium salt. In living cells, succinate dehydrogenase in the mitochondria can reduce MTT to generate a blue-purple product - formazan (soluble in DMSO), and the product has an absorption peak at 595nm, so it can be used to analyze the antiproliferative effect of the photo-released ruthenium complex on different tumor cells. 595nm To analyze cell proliferation.
[0070] The MTT assay consists of the following steps:
[0071] 1) First, thaw one tube of A549 / 5-FU tumor cells, culture them with fresh culture medium (DMEM medium + 10% fetal bovine serum + 1% penicillin and streptomycin) at 37°C, and use them after two passages.
[0072] 2) When the cells reached the logarithmic growth phase, they were seeded into two 96-well plates at a density of 10,000 cells / well (100 μL of culture medium was used to culture cells in each well, one plate was for the light group and the other was for the dark group), and cultured in a constant temperature incubator (310K, 5% CO2) at 37°C.
[0073] 3) After the cells adhere to the wall, aspirate the original culture medium, add 100 μL of different concentrations (0.01, 0.1, 1, 10, 50, 100 μM) of ruthenium complex (Ru) and 100 μL of fresh culture medium containing 5-fluorouracil (5-FU) to each well, shake gently, and incubate in a constant temperature incubator at 37°C in the dark.
[0074] 4) After incubation for 16 h, the cell culture plates in the illumination group were placed under white light for 5 min (light dose of 11.6 J / cm 2 ), the cells in the dark control group were kept in an incubator and cultured in the dark. After the illumination ended, they were returned to the incubator and continued to be incubated in the dark.
[0075] 5) After incubation for 32 h, 10 μL of MTT (5 mg / mL) was added to each well. After further incubation at 37°C for 3 h, the supernatant was removed and 100 μL of dimethyl sulfoxide (DMSO) was added to each well. A was detected using an enzyme-labeled instrument. 595 nm , calculate the cell proliferation inhibition rate and find the IC 50 value (drug concentration when the inhibition rate is equal to 50%).
[0076] like Figure 7 The MTT test results show that different concentrations of light-released ruthenium complexes and 5-FU have different killing effects on A549 / 5-FU under dark and light conditions. Ruthenium complexes have almost no toxicity to A549 / 5-FU in the absence of light, but have a strong growth inhibitory ability against A549 / 5-FU tumor cell lines under light conditions (IC 50 =0.66mM), while the chemotherapy drug 5-FU (IC 50 >200mM) is far less effective than the light-releasing complex of the present invention in inhibiting the growth of tumor cells under the same experimental conditions, which proves that the light-releasing ruthenium complex of the present invention has great potential for being developed into a highly efficient and low-toxic photochemotherapeutic drug.
[0077] In summary, the light-released ruthenium complex provided by the present invention can be applied to the field of photochemotherapy against drug resistance of non-small cell lung cancer, and has a strong growth and proliferation inhibition ability (IC 50 The ruthenium complex can release the ligand and form an endoperoxide under light conditions, thereby exposing the metal center. This is of great significance for studying new light-released ruthenium complexes to fight drug-resistant tumors, and provides a new idea for the clinical development of photochemotherapeutic drugs for drug-resistant tumors or metal photosensitizers for drug-resistant tumors.
[0078] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the protection scope of the present invention.
Claims
1. A light-releasing ruthenium complex, characterized in that The structure of the light-releasing ruthenium complex is shown below:
2. The method for preparing the light-releasing ruthenium complex according to claim 1, characterized in that: The following steps are involved: S1. Under the protection of inert gas, 9-anthraceneboric acid, 5-bromo-2,2'-bipyridine, tetrakis(triphenylphosphine)palladium and anhydrous potassium carbonate are dissolved in an organic solvent, and the bpy-en ligand is obtained by heating and refluxing, followed by extraction and purification. The structural formula of the bpy-en ligand is shown below: S2. Under the protection of inert gas, ruthenium chloride (III) hydrate, lithium chloride and 2,9-dimethyl-1,10-phenanthroline are dissolved in an organic solvent, and a Ru(dmp)2Cl2 precursor is obtained by reflux reaction, enrichment precipitation and precipitation washing. The structural formula of the Ru(dmp)2Cl2 precursor is as follows: S3. Dissolve the precursor Ru(dmp)2Cl2 and bpy-en ligand in an organic solvent, add a saturated aqueous solution of ammonium hexafluorophosphate after heating reaction, and obtain a light-releasing ruthenium complex after stirring reaction.
3. The method for preparing a light-released ruthenium complex according to claim 2, characterized in that: In step S1, the molar ratio of 9-anthraceneboric acid, 5-bromo-2,2'-bipyridine and anhydrous potassium carbonate is 1:1:3, and the amount of tetrakis(triphenylphosphine)palladium is 3 mol%.
4. The method for preparing a light-released ruthenium complex according to claim 2, characterized in that: In step S1, the heating reflux reaction is a heating reflux reaction at 100-115° C. for 8-15 hours.
5. The method for preparing a light-released ruthenium complex according to claim 2, characterized in that: In step S2, the reflux reaction time is 8 to 15 hours.
6. The method for preparing a light-released ruthenium complex according to claim 2, characterized in that: In step S2, the molar ratio of the ruthenium (III) chloride hydrate, lithium chloride and 2,9-dimethyl-1,10-phenanthroline is 3:8.9:
6.
7. The method for preparing a light-released ruthenium complex according to claim 2, characterized in that: In step S3, the molar ratio of the bpy-en ligand to the precursor Ru(dmp)2Cl2 is 1:
1.
8. The method for preparing a light-released ruthenium complex according to claim 2, characterized in that: In step S3, the heating reaction is performed at 80-85° C. for 8-15 hours.
9. Use of the light-released ruthenium complex according to claim 1 in the preparation of a drug for treating 5-fluorouracil resistance in non-small cell lung cancer.
10. A photochemotherapeutic anti-resistant tumor drug or anti-tumor metal photosensitizer, characterized in that: The drug or photosensitizer has the light-releasing ruthenium complex described in claim 1 as a main active ingredient.
